Friday, 29 May 2015

Regenerative Medicines Brings Hope For Those Combating Parkinson’s’ Disease

Report Overview
Growing concerns over diseases that often worsens with age such as Dementia or Parkinson’s disease has drawn the attention of major Pharmaceutical companies, who are now considering acquisitions and are involved in partnership with emerging research enterprises. This momentum has favoured the PD therapeutics market with the rise of regenerative medicine that is now organised around latest medical technologies potentially having solutions for reversing the aging process in humans. The PD therapeutics market that has existed for over two decades marked by several early stage start-ups focused around the application of the stem cells.

Despite, the fact the significant demand in the pathogenesis, diagnosis as well as treatment algorithms was observed over the last four to five years in nations such as Italy , United States , Italy , Canada , France, Japan, United Kingdom and Germany. The developments in therapeutics pertaining to the Parkinson’s disease are driven by advancements in certain areas of technology comprising of tissues engineering, electroceuticals, lead in stem cell treatments, and nanotechnology.

Get Detailed info about Dementia or Pakinson's Disease at:

The University of Cambridge leading a reviving procedure made a breakthrough by injecting fetal cells into a 50 year old brain with the intent to cure his Parkinson’s disease and to everyone’s surprise he gained full control over his movements in five years. In another breakthrough Contera Pharma announced that it has already started working on PD treatment paired with Denmark based Solural Pharma and Germany based Erweka GmbH and Ernst Moritz Arndt University of Greifswald. John Bondo Hansen, CEO of Contera Pharma says “It is an honor to carry out this project through cooperation with partner companies in Denmark and Germany. The project is one of our development portfolio, which focuses on developing new treatments for various degenerative movement disorders. Our goal is to improve the quality of life of patients and their families.”

Recently, a report added by Research Beam titled “Parkinson's Disease Therapeutics Market to 2019” which  indicate that the geographically driven changes that are raising interest of the major pharmaceutical companies have now persuaded them to partner up with emerging biotechnology enterprises in developing treatments for Parkinson Diseases. To top it all, the initiatives taken in effectively combating the early motor symptoms of the aforesaid disease would trigger growth in the Parkinson’s’ Disease therapeutics.

No comments:

Post a Comment